Business
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net sa
About this update from Prelude Therapeutics Incorporated
[{"type":"image","alt":"Prelude Therapeutics, Incorporated","displaySize":"","headline":null,"caption":"Prelude Therapeutics, Incorporated","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9HVZo7WrFLmSMiAVkGF1.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555","width":300,"height":103}},"lazy":false},{"type":"text","content":"Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program","length":104,"tagName":"p"},{"type":"text","content":"Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs)","length":143,"tagName":"p"},{"type":"text","content":"Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net salesPrelude will continue to develop all JAK2V617F program assets during the option period; if optioned, Incyte would lead development and commercialization globally","length":417,"tagName":"p"},{"type":"text","content":"WILMINGTON, Del., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq:PRLD), a clinical-stage precision oncology company, today announced an exclusive option agreement with Incyte (Nasdaq:INCY) focused on Prelude’s previously undisclosed mutant selective JAK2V617F JH2 inhibitor program in development for patients with myeloproliferative neoplasms (MPNs). Per the agreement, Incyte secures an exclusive option to acquire the JAK2V617F program in exchange for an upfront payment and a strategic equity investment in Prelude, plus potential downstream milestones and royalties.","length":600,"tagName":"p"},{"type":"text","content":"Kris Vaddi, Ph.D., Chief Executive Officer of Prelude stated, “We’re pleased to put this agreement in place with Incyte, recognized global leaders in the MPN field. Prelude and Incyte both aim to deliver transformational treatments to improve upon the standard of care established with first generation JAK2 JH1 inhibitors l...